Mecademic, a Canadian manufacturer of compact industrial robots, has raised CAD 21 million (USD 15.3 million) in funding led by Investissement Québec, with participation from Export Development Canada and the Business Development Bank of Canada. The company will use the funds to drive product innovation, international expansion and construct new headquarters. Mecademic plans significant investments in the US, European and Asia-Pacific markets, expanding applications of its ultra-compact robotic arms in electronics, optics, medical devices and biotechnology sectors. Since 2022, Mecademic has transformed into a growth-oriented global organisation, strengthening its governance structure with new appointments including Dominique Jodoin as chairman and David Massé as chief financial officer. The company maintains leadership in micro-automation, where its robots integrate precise automation into confined spaces unsuitable for traditional robots.

The Business Development Bank of Canada has launched a $150-million fund to invest directly in life sciences companies, marking a return to the sector after years away. The fund will target seed- and Series A-stage therapeutics and medical technology companies, writing cheques between $1 million and $3 million at seed stage and $5 million to $8 million at Series A. Parimal Nathwani, former head of Toronto life sciences incubator TIAP, will manage the fund as managing partner. BDC aims to back 10 to 15 companies over the fund's lifecycle. The move addresses a funding gap in Canadian life sciences, which saw investment drop 47% year-over-year to $837 million in 2025. The $150-million envelope comes from fresh capital off BDC's balance sheet.

Flora Fertility has raised $5 million in seed funding led by ManchesterStory, with participation from Slauson & Co., BDC, Adara Venture Partners and existing investors. The Canadian startup offers subscription-based reproductive insurance starting at $20 monthly, covering diagnostics, medications, IUI and IVF. The platform addresses a significant gap in fertility care access. Globally, one in six people face infertility, yet fewer than 2% can afford treatment, with IVF costs ranging from $15,000 to $30,000 per cycle in the US. Unlike employer-tied benefits, Flora's individually owned policies remain portable across job changes. The company currently reaches over 10 million prospective policyholders across North America. The funding will support expansion as the global femtech market grows towards a projected $267 billion by 2035.